Torren Management’s Harmony Biosciences HRMY Stock Holding History

Torren Management’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15	Closed	-$561	–	1195
2025 Q4	$561	Buy	+15	New	+$493	﹤0.01%	1311

Other funds holding HRMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Torren Management's HRMY Position: Q1 2026 in Review

Torren Management sold out of Harmony Biosciences (HRMY) in Q1 2026, closing a stake of 15 shares — an estimated $561 sold.

Torren Management first reported a position in HRMY in Q4 2025 and held it in 1 quarter. The position peaked at $561 in Q4 2025. 310 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

Torren Management reported no remaining Harmony Biosciences position as of Q1 2026 after selling out during the quarter.
Torren Management sold 15 Harmony Biosciences shares in Q1 2026, an estimated $561.
Torren Management first reported a position in Harmony Biosciences in Q4 2025 and held it in 1 quarter.
Torren Management's Harmony Biosciences position peaked at $561 in Q4 2025.
310 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Torren Management's 13F filing for Q1 2026, filed 30 Apr 2026.